Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (539)	5/6/1999 2:24:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

ARIAD Completes Phase 1 Clinical Trial On Gene Regulation Drug to Treat Graft-Versus-Host Disease First Clinical Study of ARGENT(TM) Dimerizer Drug(TM) biz.yahoo.com I suppose it is no surprise that ARIA is only up 1/32 as I type this, the market probably does not react to phase I results, unless of course you manage to kill somebody. AP1903 was well tolerated at all dose levels, and there were no drug-related adverse events. Pharmacokinetics analysis demonstrated a direct dose-proportional relationship between the dose administered and the drug plasma concentrations. Plasma concentrations were obtained that exceeded anticipated therapeutic drug concentrations. ''Successful completion of the Phase 1 clinical trial of our first Dimerizer Drug(TM) is an important milestone for ARIAD,'' said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. ''The availability of a reliable way to control GvHD, without the need for immunosuppression, should make allogeneic bone marrow transplantation safer and more effective for patients with cancer. We plan on initiating Phase 2 clinical trials later this year.'' Still, a market cap of 30M does seem awfully low for a company with such a seemingly elegant solution...I will not argue the fact that the stock is dead, but the company itself still lives--albeit marching along v e r y s l o w l y --at least from a shareholder's perspective.